EICHORCondition: Haemophilia A With Inhibitors · Haemophilia B With Inhibitors · Sponsor: Novo Nordisk A/S
Sponsor, CRO or site team? See where this study is running → — listed sites, countries and recruiting context. Everything below is written for patients and caregivers.
This study will test how well a new medicine called concizumab works in the body of people with haemophilia A or B with inhibitors. The purpose is to show that concizumab can prevent bleeds in the body and is safe to use. Participants who usually only take medicine to treat bleeds (on-demand) will be placed in one of two groups. In one group, participants will get study medicine from the start of the study. In the other group, participants will continue with their normal medicine and get study medicine after 6 months. Which treatment the participant gets is decided by chance. Participants who usually take medicine to prevent bleeds (prophylaxis treatment) or who are already being treated with concizumab (study medicine) will receive the study medicine from the start of the study. Participants will get 1 injection with the study medicine every day under the skin. This participants will have to do themselves and can be done at home. The study doctor will hand out the medicine in the form of a pen-injector. The pen-injector will contain the study medicine. The study will last for about seven years. The length of time the participants will be in the study depends on when they agreed to take part or when the medicine is available for purchase in their country (31 December 2026 at the latest). The time between visits will be approximately 4 weeks for the first 6 to 12 months, depending on the group participants are in and approximately 8 weeks for the rest of the study. Participant…
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| Center for Inherited Blood Dis | Orange, California, United States | — |
| Children's Healthcare Atlanta | Atlanta, Georgia, United States | — |
| Indiana Hemophilia-Thromb Ctr | Indianapolis, Indiana, United States | — |
| Washington University School of Medicine_St. Louis | St Louis, Missouri, United States | — |
| St. Jude Affiliate Clinic at Novant Health Hemby Children's | Charlotte, North Carolina, United States | — |
| TriStar Medical Group Children's Specialist | Nashville, Tennessee, United States | — |
| University of Texas San Antonio | San Antonio, Texas, United States | — |
| Haematology and Blood Bank Department | Algiers, Algeria | — |
| CHU Constantine BEN BADIS/ Hematology department | Constantine, Algeria | — |
| The Alfred | Melbourne, Victoria, Australia | — |
| The Royal Children's Hospital | Parkville, Victoria, Australia | — |
| Fiona Stanley Hospital - Haemophilia and Haemostasis Centre | Murdoch, Western Australia, Australia | — |
+ 87 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04083781